NCT02035748

Assessment of Patients Treated With JETREA® for Vitreomacular Traction

Assessment of Anatomical and Functional Outcomes in Patients Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 628 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.

Detailed description

After receiving a single intravitreal injection as per country's product label (Day 0), subjects were followed for a 6-month period (Day 180).

Conditions

• Vitreomacular Traction
• Vitreomacular Adhesion

Interventions

Type	Name	Description
DRUG	Ocriplasmin	0.5 mg/0.2 mL solution for injection

Timeline

• Start date: 2014-04-01
• Primary completion: 2015-09-01
• Completion: 2015-09-01
• First posted: 2014-01-14
• Last updated: 2016-10-12
• Results posted: 2016-10-12